<SEC-DOCUMENT>0001213900-22-014838.txt : 20220324
<SEC-HEADER>0001213900-22-014838.hdr.sgml : 20220324
<ACCEPTANCE-DATETIME>20220324160100
ACCESSION NUMBER:		0001213900-22-014838
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220321
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220324
DATE AS OF CHANGE:		20220324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38793
		FILM NUMBER:		22766443

	BUSINESS ADDRESS:	
		STREET 1:		225 NE MIZNER BLVD, SUITE 640
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		225 NE MIZNER BLVD, SUITE 640
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea157245-8k_inmunebio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:INMB="http://inmunebio.com/20220321">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_INMB_inmunebio.com_20220321 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20220321_20220321 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001711754 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:EntityCentralIndexKey">0001711754</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="inmb-20220321.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-03-21to2022-03-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-21</xbrli:startDate>
        <xbrli:endDate>2022-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90F_edei--DocumentType_c20220321__20220321_zWtnGb9i1BV7"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_900_edei--DocumentPeriodEndDate_c20220321__20220321_zfbAQ1fWi2k6"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 21, 2022</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 25%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 50%; text-align: center"><b><span id="xdx_902_edei--EntityRegistrantName_c20220321__20220321_zMT58hlWq2hg"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:EntityRegistrantName">INMUNE BIO INC.</ix:nonNumeric></span></b></td>
    <td style="width: 25%; text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">(Exact name of registrant as specified in charter)</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20220321__20220321_zFfNmkVzcEhe"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><b><span id="xdx_905_edei--EntityFileNumber_c20220321__20220321_z2BNVtKTb8C7"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:EntityFileNumber">001-38793</ix:nonNumeric></span></b></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20220321__20220321_z2yH7nYTMrij"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:EntityTaxIdentificationNumber">47-5205835</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(State or other jurisdiction</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">(Commission File Number)</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">(IRS Employer</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">of incorporation)</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">Identification No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityAddressAddressLine1_c20220321__20220321_zfm69vZkffA8"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:EntityAddressAddressLine1">225 NE Mizner Blvd</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20220321__20220321_zqNeF02ixTFf"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:EntityAddressAddressLine2">Suite 640</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressCityOrTown_c20220321__20220321_zr0JzscvaGKi"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:EntityAddressCityOrTown">Boca Raton</ix:nonNumeric></span>
<span id="xdx_904_edei--EntityAddressStateOrProvince_c20220321__20220321_z3KI9yQ59I9a"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20220321__20220321_z89s1JMFk5o"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:EntityAddressPostalZipCode">33432</ix:nonNumeric></span> </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">(<span id="xdx_909_edei--CityAreaCode_c20220321__20220321_zVTV9TnnoFfk"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:CityAreaCode">858</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20220321__20220321_zX3jgqXq08K7"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:LocalPhoneNumber">964 3720</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">Not Applicable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, If Changed Since
Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration: underline">see</span>
General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--WrittenCommunications_c20220321__20220321_zcigpzGzX8T6"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--SolicitingMaterial_c20220321__20220321_zGeVzdNt5Atd"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20220321__20220321_zBFDjXyJtuG7"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20220321__20220321_zCx6pQCFR6fi"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><b>Title of each class</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><b>Trading Symbol(s)</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center"><span id="xdx_905_edei--Security12bTitle_c20220321__20220321_zsvAb044T3r4"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:Security12bTitle">Common Stock, par value $0.001 per shares</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_edei--TradingSymbol_c20220321__20220321_zAaxtev2K3Vb"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" name="dei:TradingSymbol">INMB</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center">The <span id="xdx_90F_edei--SecurityExchangeName_c20220321__20220321_zqud4mgWqAV"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20220321__20220321_zIgl975VSHE3"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityExTransitionPeriod_c20220321__20220321_zhFpsHKB1e4c"><ix:nonNumeric contextRef="From2022-03-21to2022-03-21" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As previously
reported on a Current Report on Form 8-K that was filed with the Securities and Exchange Commission on June 3, 2021, on June 1, 2021,
the stockholders of </span>INmune Bio, Inc. <span style="background-color: white">(the &#8220;Company&#8221;) approved the Company&#8217;s
2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;), pursuant to which 2,000,000 shares of the Company&#8217;s common stock will be
made available for issuance under the 2021 Plan. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On March
21, 2022, the Compensation Committee of the Board of Directors of the Company approved the issuance of option for the non-employee directors
to purchase an aggregate of up to 175,000 shares of the Company&#8217;s common stock. As such, each non-employee director (&#8220;Optionee&#8221;)
was granted an option to purchase 35,000 shares of the Company&#8217;s common stock with an exercise price of $7.92. One third (1/3) of
the options will vest at the one-year anniversary of date of grant and the remaining unvested option will become vested and exercisable
1/24th every month thereafter until the option is 100% vested, which shall occur on the three-year anniversary of the date of grant. The
options were granted from the 2021 Plan. The Company will execute a stock option agreement with each Optionee. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On March
21, 2022, the Compensation Committee of the Board of Directors of the Company approved the issuance of options to Ramond J. Tesi, the
Company&#8217;s Chief Executive Officer, and David Moss, the Company&#8217;s Chief Financial Officer, pursuant to which Dr. Tesi and Mr.
Moss may each purchase up to 130,000 shares of common stock at an exercise price of $7.92 per share</span>. <span style="background-color: white">In
addition, the Company approved the issuance of an option to Mark Lowdell, the Company&#8217;s Chief Scientific Officer, to purchase up
to 104,000 shares of common stock at an exercise price of $7.92 per share. One third (1/3) of the options will vest at the one-year anniversary
of date of grant and the remaining unvested option will become vested and exercisable 1/24th every month thereafter until the option is
100% vested, which shall occur on the three-year anniversary of the date of grant. The options were granted from the 2021 Plan. The Company
will execute a stock option agreement with Dr. Tesi, Mr. Moss and Mr. Lowdell. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The option grants referenced above are qualified
by reference to the form of option agreement which is being filed as exhibit to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following exhibits are being filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><b>Exhibit&#160;No</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><b>Description </b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.1</td>
    <td>&#160;</td>
    <td><a href="ea157245ex10-1_inmunebio.htm">Form of Option Agreement between the Company and Non-Employee Directors and consultants&#160;</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>10.2</td>
    <td>&#160;</td>
    <td><a href="ea157245ex10-2_inmunebio.htm">Form of Option Agreement for Employees of the Company</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><b>INMUNE BIO INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%; text-align: justify">Date: March 24, 2022</td>
    <td style="width: 5%; text-align: justify">By:</td>
    <td style="border-bottom: black 1.5pt solid; width: 35%; text-align: justify"><i>/s/ David Moss</i></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">David Moss</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Chief Financial Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Wko36sLLpCSyCJHodssxlnRHZrcfH6m3bFOi4cAwnPPNESIUGa11gwynZZFDiW3XKIdQYI2M5oI+kW62Cfhd4FVbx8q44fyBKXkGPTOfxPLsjSH60BarBKLZVEoviGQiF3DYieDrp2RqXaFxWjWgTAUHpo41OsX9+KFULzLU9kPVEdlqMgnEk2i03yCjWMKeHupJfLOQ56kIwmECkTHdu2/N3TpqYdVg67vsiP4VfAAVU0lF -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea157245ex10-1_inmunebio.htm
<DESCRIPTION>FORM OF OPTION AGREEMENT BETWEEN THE COMPANY AND NON-EMPLOYEE DIRECTORS AND CONSULTANTS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INMUNE BIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2021 STOCK INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nonqualified Stock Option Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <B>NONQUALIFIED STOCK
OPTION AGREEMENT</B> (this &ldquo;<U>Agreement</U>&rdquo;), made and entered into on the 21st day of March 2022, by and between (the &ldquo;<U>Participant</U>&rdquo;)
and INmune Bio, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), sets forth the terms and conditions of stock options issued
to the Participant by the Compensation Committee of the Board of Directors of the Company on March 21, 2022 (the &ldquo;<U>Grant Date</U>&rdquo;)
pursuant to the Company's 2021 Stock Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;) and this Agreement, which options have been approved
by the Company&rsquo;s Board of Directors. Any capitalized terms used but not defined herein shall have the meaning prescribed in <U>Annex
A</U> or in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Grant of Stock Option.</U> Subject to the provisions of this Agreement and the Plan, the Company hereby grants to the Participant
a nonqualified stock option (the &ldquo;<U>Option</U>&rdquo;) to purchase up to shares of the Company's common stock, $0.001 par value
per share (the &ldquo;<U>Common Stock</U>&rdquo;). The Option are granted as of the Grant Date pursuant to, and subject to the terms and
conditions of, the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Exercise Price</U>.&nbsp;The exercise price per share of Common Stock subject to the Options is $7.92 (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Vesting</U>.&nbsp;Subject to Section 4 hereof, one third (1/3) of the Option granted will vest 12 months from the Grant Date and
thereafter the remaining unvested Option will become vested and exercisable pro rata on a monthly basis over two (2) years (1/24 per month)
until the Option is 100% vested which shall occur on the three-year anniversary of the Grant Date so long as (and provided that) the Participant
continuously remains an employee, officer, director, or consultant of the Company from the Grant Date through such date(s). The Options
shall be exercisable on any date to the extent vested and outstanding on such date. For purposes of this Agreement, employment or service
relationship with the Company shall include employment with or provision of services to the Company's affiliates (including Subsidiaries)
and/or its successors. As set forth in Section 12 herein, nothing in this Agreement or the Plan shall confer upon the Participant any
right to continue in the employ or service of the Company or any of its affiliates (including Subsidiaries) or interfere in any way with
the right of the Company or any such affiliates (including Subsidiaries) to terminate the Participant's employment or service relationship
at any time. In the event of any &ldquo;Change of Control&rdquo;, all of the options granted hereunder shall automatically and immediately
vest. For purposes of this Option, the term Change of Control shall mean: the sale of all or substantially all of the assets of the Company;
any merger, consolidation or acquisition of the Company with, by or into another corporation, entity or person which results in another
party acquiring more than 50% of the entity. To avoid ambiguity, the Participant acknowledges that a reverse merger of the Company into
a public entity wherein the pre-merger shareholders of the Company still own more than 50.1% of the combined company shall not constitute
a Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> &nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Termination of Employment or Service</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>In the event of the Participant's termination of employment or service relationship, whether as an employee, officer, director
or consultant, by either the Company or its affiliates (including Subsidiaries) without Cause, or by the Participant, any portion of the
Options that has not vested as of the date of such termination of employment or service relationship shall immediately expire, and the
vested Options shall expire within 90 days after such termination of employment or service relationship. In the event of the Participant's
termination of employment or service relationship by reason of the Participant's death or Disability, the vested Options shall expire
within 180 days after such termination of employment or service relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>In the event of the Participant's termination of employment or service relationship, whether as an employee, officer, director
or consultant, by the Company or its affiliates (including Subsidiaries) for Cause, any portion of the Options that are outstanding as
of the date of such termination of employment or service relationship shall immediately be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Term of Options</U>.&nbsp;All unexercised Options shall expire as to all shares of Common Stock underlying the Options on March
20, 2032 (the &ldquo;<U>Expiration Date</U>&rdquo;), unless sooner terminated as provided in Section 4 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Method of Stock Option Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Options may be exercised during their term, in whole or in part, to the extent they have become vested and exercisable pursuant
to Sections 3 and/or 4 and have not yet been forfeited or expired, by the Participant providing notice in writing to the Chief Executive
Officer of the Company (the &ldquo;<U>CEO</U>&rdquo;), signifying the Participant&rsquo;s election to exercise the Options (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). The Notice of Exercise shall be in such manner and on such form as designated by the CEO and pursuant to procedures
established by the CEO and/or the Company. The Company may in the future change the person designated to receive such Notice(s) of Exercise,
to any other agent or employee of the Company. In the event of any such change, the Company shall provide notice to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The payment of the Exercise Price shall be subject to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Payment of Exercise Price</U>. The Exercise Price shall be payable in cash or by wire transfer to the Company&rsquo;s bank account,
for the full purchase price of the shares being purchased, plus such amount, if any, as is required for withholding taxes and for fees
related to any agent(s), if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>If requested by the Company, a written acknowledgement by the Participant, in the form contained in the Notice of Exercise that
an investment in the Common Stock of the Company involves a high degree of risk, that the Participant has received a copy of the Company's
financial statements for the most recently ended fiscal year for which such statement is available, and that the Participant has had the
opportunity to ask questions of management concerning the Company prior to the exercise of the Options (the Company to provide such information
as the Participant may reasonably request in writing, provided that such information has been disclosed to the public).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Exercise Price per share of Common Stock purchased upon the exercise of the Options shall be paid at the time of such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>The Company may cause each certificate evidencing the purchased Common Stock to be endorsed with one or more legends setting forth
the restrictions on transfer or otherwise of such Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>Certificates for shares of the Common Stock so purchased will be issued as soon as practicable. The Company, however, shall not
be required to issue or deliver a certificate for any shares until it has complied with all requirements of the Securities Act of 1933,
as amended, the Securities Exchange Act of 1934, as amended, any stock exchange on which the Company&rsquo;s Common Stock may then be
listed and all applicable state laws in connection with the issuance or sale of such shares or the listing of such shares on said exchange.
Until the issuance of the certificate for such shares, the Participant, or such other person as may be entitled to exercise these Options,
shall have none of the rights of a stockholder with respect to shares subject to the Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Taxes</U>. Participant understands that, upon the exercise of the Option, Participant may recognize income, for federal and
state income tax purposes. The acceptance of the shares underlying the Option by the Participant shall constitute an agreement by the
Participant to report such income in accordance with then applicable law and to cooperate with the Company in establishing the amount
of such income and corresponding deduction to the Company for its income tax purposes. Withholding for federal or state income and employment
tax purposes will be made, if and as required by law, from Participant&rsquo;s then current compensation, or, if such current compensation
is insufficient to satisfy withholding tax liability, the Company may require the Participant to make a cash payment to cover such liability
as a condition of the exercise of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Non-transferability</U>. The Options shall not be transferable by the Participant (as defined below) other than pursuant to
the terms of the Plan or by will or by the laws of descent and distribution. The Options shall be exercisable, subject to the terms of
the Plan and this Agreement, only by the Participant, the Participant's estate or beneficiary, the guardian or legal representative of
the Participant, or any person to whom such Options are transferred pursuant to this Section 8. For purposes of this Section 8, the term
&ldquo;Participant&rdquo; includes such guardian, legal representative and other permitted transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Successors, Assigns and Transferees</U>. This Agreement shall be binding upon, and inure to the benefit of, the parties hereto
and each of their respective successors, assigns and permitted transferees (including, upon the death of the Participant, the Participant's
estate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Administration</U>. The authority to manage and control the operation and administration of this Agreement shall be vested in
the Committee, and the Committee shall have all powers with respect to this Agreement as it has with respect to the Plan. In the event
of any question or controversy relating to the terms of the Plan and this Agreement, the decision of the Committee shall be conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Incorporation of Plan</U>. Subject to the limitations contained in Section 10 of this Agreement, all terms and conditions of
the Plan are incorporated herein and made part hereof as if stated herein. The Participant may obtain a copy of the Plan by contacting
the Company's Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Not an Employment or Service Contract</U>. Neither this Agreement nor any Options, or the Plan, shall confer on the Participant
any right with respect to continuance of employment or other service with the Company or any of its affiliates (including Subsidiaries),
nor shall they interfere in any way with any right(s) that the Company or any such affiliates (including Subsidiaries) would otherwise
have to terminate or modify the terms of the Participant's employment or other service, at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Insider Trading Policy</U>. The Participant hereby certifies as to his agreement to comply with any policies, instructions,
guidelines or procedures covering trading in the Company&rsquo;s securities that the Company adopts from time to time, as may relate to
the Options and underlying shares issued hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Exercise on certain Record Dates</U>. Notwithstanding anything to the contrary contained in this Agreement or the Plan, in the
event the Company sets a record date (&ldquo;<U>Record Date</U>&rdquo;) in connection with a distribution of bonus shares or dividends,
rights offering, stock split, reverse stock split or capital reduction (each an &ldquo;<U>Event</U>&rdquo;), the Participant shall not
be eligible to exercise the Options on the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Integration</U>. This Agreement and the other documents referred to herein, including without limitation the Plan, or delivered
pursuant hereto, which form a part hereof contain the entire understanding of the parties with respect to their subject matter. There
are no restrictions, agreements, promises, representations, warranties, covenants or undertakings with respect to the subject matter hereof
other than those expressly set forth herein. This Agreement, including without limitation the Plan, supersedes all prior agreements and
understandings between the parties with respect to its subject matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
which together constitute one and the same instrument. Notwithstanding the foregoing, any duly authorized officer of the Company may execute
this Agreement by providing an appropriate facsimile signature and any counterpart or amendment hereto containing such facsimile signature
shall for all purposes be deemed an original instrument duly executed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Modification; Waiver</U>. No provision of this Agreement may be amended, modified, or waived unless such amendment or modification
is agreed to in writing and signed by the Participant and by a duly authorized officer of the Company, and such waiver is set forth in
writing and signed by the party to be charged. No waiver by either party hereto at any time of any breach by the other party hereto of
any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions
or conditions at the same or at any prior or subsequent time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS AGREEMENT SHALL BE NULL AND VOID <I>AB
INITIO</I>, AND THE GRANT OF OPTIONS REFLECTED HEREIN, SHALL BE DEEMED FORFEITED, UNLESS THE COMPANY RECEIVES, WITHIN TWO WEEKS OF ITS
TENDER OF THIS AGREEMENT TO THE PARTICIPANT, ONE COPY HEREOF BEARING THE PARTICIPANT&rsquo;S ORIGINAL COUNTERSIGNATURE BELOW.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>SIGNATURE PAGE FOLLOWS</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Participant
has executed this Agreement on the Participant's own behalf, thereby representing that the Participant has carefully read and understands
this Agreement and the Plan as of the day and year first written above, and the Company has caused this Agreement to be executed in its
name and on its behalf, all as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">INMUNE BIO, INC.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD> Raymond J. Tesi</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD> President &amp; CEO</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Agreed to and Accepted</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">this 21st day of March 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Annex A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Certain Definitions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A.&nbsp;
&ldquo;Cause&rdquo; shall only mean</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the willful and continued failure of the Participant to perform substantially the Participant&rsquo;s
duties (other than any such failure resulting from bodily injury or disease or any other incapacity due to mental or physical illness)
after a written demand for substantial performance is delivered to the Participant by the Company, which specifically identifies the manner
in which the Company believes the Participant has not substantially performed the Participant&rsquo;s duties; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the willful engaging by the Participant in illegal conduct or gross misconduct that is materially and
demonstrably detrimental to the Company and/or its affiliates (including Subsidiaries), monetarily or otherwise.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">For purposes of this
provision, no act, or failure to act, on the part of the Participant shall be considered &ldquo;willful&rdquo; unless done, or omitted
to be done, by the Participant in bad faith or without reasonable belief that the Participant&rsquo;s action or omission was in the best
interests of the Company. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the Board, upon
the instructions of the Chairman or another Board Member of the Company, upon the instructions of the Company's Chief Executive Officer
or Chief Financial Officer, or based upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted
to be done, by the Participant in good faith and in the best interests of the Company and its affiliates (including Subsidiaries).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the Participant&rsquo;s conviction of, or plea of nolo contendere to, any felony of theft, fraud, embezzlement
or violent crime.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B.&nbsp;&ldquo;Disability&rdquo;
shall mean the absence of the Participant from the Participant&rsquo;s duties under his employment or service relationship on a full-time
basis for an aggregate of 180&nbsp;days within any given period of 270 consecutive days (in addition to any statutorily required leave
of absence and any leave of absence approved by the Company) as a result of incapacity of the Participant, despite any reasonable accommodation
required by law, due to bodily injury or disease or any other mental or physical illness, which will, in the opinion of a physician selected
by the Company or its insurers and acceptable to the Participant or the Participant&rsquo;s legal representative, be permanent and continuous
during the remainder of the Participant&rsquo;s life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">6</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea157245ex10-2_inmunebio.htm
<DESCRIPTION>FORM OF OPTION AGREEMENT FOR EMPLOYEES OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
Stock Option Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Incentive Stock Option Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of March 21, 2022 by and between INmune
Bio, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;) and (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
Date: March 21, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
Price per Share: $7.92</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Option Shares:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
Date: March 20, 2032</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">1.&nbsp;
<FONT STYLE="background-color: white"><U>Grant of Option</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">1.1&nbsp;
<U>Grant; Type of Option</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company hereby grants
to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the total number of shares of Common Stock of the Company equal
to the number of Option Shares set forth above, at the Exercise Price set forth above. The Option is being granted pursuant to the INmune
Bio 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended to be an Incentive Stock Option within the meaning
of Section 422 of the Code, although the Company makes no representation or guarantee that the Option will qualify as an Incentive Stock
Option. To the extent that the aggregate Fair Market Value (determined on the Grant Date) of the shares of Common Stock with respect
to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year (under all plans of the
Company and its Affiliates) exceeds $100,000, the Options or portions thereof which exceed such limit (according to the order in which
they were granted) shall be treated as Non-Qualified Stock Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">1.2&nbsp;<U>Consideration; Subject to Plan</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The grant of
the Option is made in consideration of the services to be rendered by the Participant to the Company and is subject to the terms and
conditions of the Plan. Capitalized terms used but not defined herein will have the meaning ascribed to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.&nbsp;
<FONT STYLE="background-color: white"><U>Exercise Period; Vesting</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.1&nbsp;
<U>Vesting Schedule</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. One third (1/3) of the Option
will vest at the one-year anniversary of the Grant Date and the remaining unvested Option will become vested and exercisable 1/24<SUP>th
</SUP>every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the Grant Date. The unvested
portion of the Option will not be exercisable on or after the Participant&rsquo;s termination of Continuous Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.2&nbsp;<U>Expiration</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Option will expire on the Expiration
Date set forth above, or earlier as provided in this Agreement or the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.&nbsp;
<FONT STYLE="background-color: white"><U>Termination of Continuous Service</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.1&nbsp;<U>Termination for Reasons Other Than Cause, Death, Disability</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If the Participant&rsquo;s Continuous Service is terminated for any reason other than Cause, death or Disability, the Participant may exercise
the vested portion of the Option, but only within such period of time ending on the earlier of (a) the date three months following the
termination of the Participant&rsquo;s Continuous Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.2&nbsp;<U>Termination for Cause</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If the Participant&rsquo;s Continuous
Service is terminated for Cause, the Option (whether vested or unvested) shall immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.3&nbsp;<U>Termination due to Disability</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If the Participant&rsquo;s
Continuous Service terminates as a result of the Participant&rsquo;s Disability, the Participant may exercise the vested portion of the Option,
but only within such period of time ending on the earlier of (a) the date 12 months following the Participant&rsquo;s termination of Continuous
Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.4&nbsp;<U>Termination due to Death</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If the Participant&rsquo;s
Continuous Service terminates as a result of the Participant&rsquo;s death, the vested portion of the Option may be exercised by the Participant&rsquo;s
estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by the person designated to exercise the
Option upon the Participant&rsquo;s death, but only within the time period ending on the earlier of (a) the date 12 months following the Participant&rsquo;s
death or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.&nbsp;
<FONT STYLE="background-color: white"><U>Manner of Exercise</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.1&nbsp;
<U>Election to Exercise</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. To exercise the Option,
the Participant (or in the case of exercise after the Participant&rsquo;s death or incapacity, the Participant&rsquo;s executor, administrator, heir
or legatee, as the case may be) must deliver to the Company a notice of intent to exercise in the manner that is reasonably acceptable
to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.2&nbsp;<U>Payment of Exercise Price</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The entire Exercise
Price of the Option shall be payable in full at the time of exercise in the manner designated by the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.3&nbsp;<U>Withholding</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If the Company, in its discretion,
determines that it is obligated to withhold any tax in connection with the exercise of the Option, the Participant must make arrangements
satisfactory to the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The
Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise of the Option by any of the following
means or by a combination of such means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;
tendering a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;
authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a
result of the exercise of the Option; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum
amount of tax required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;
delivering to the Company previously owned and unencumbered shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to a Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.4&nbsp;
<U>Issuance of Shares</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Provided that the exercise
notice and payment are in form and substance satisfactory to the Company, the Company shall issue the shares of Common Stock registered
in the name of the Participant, the Participant&rsquo;s authorized assignee, or the Participant&rsquo;s legal representative which shall be evidenced
by stock certificates representing the shares with the appropriate legends affixed thereto, appropriate entry on the books of the Company
or of a duly authorized transfer agent, or other appropriate means as determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">5.&nbsp;
<FONT STYLE="background-color: white"><U>No Right to Continued Employment; No Rights as Shareholder</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Neither the Plan nor this Agreement shall confer upon the Participant any right to be retained in any position, as an Employee, Consultant
or Director of the Company. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company
to terminate the Participant&rsquo;s Continuous Service at any time, with or without Cause. The Participant shall not have any rights as a
shareholder with respect to any shares of Common Stock subject to the Option unless and until certificates representing the shares have
been issued by the Company to the holder of such shares, or the shares have otherwise been recorded on the books of the Company or of
a duly authorized transfer agent as owned by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">6.&nbsp;<FONT STYLE="background-color: white"><U>Transferability</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Option is not transferable by the Participant other than to a designated beneficiary upon the Participant&rsquo;s death or by will or the
laws of descent and distribution, and is exercisable during the Participant&rsquo;s lifetime only by him or her. No assignment or transfer
of the Option, or the rights represented thereby, whether voluntary or involuntary, by operation of law or otherwise (except to a designated
beneficiary upon death by will or the laws of descent or distribution) will vest in the assignee or transferee any interest or right
herein whatsoever, but immediately upon such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">7.&nbsp;<U>Merger, Consolidation or Asset Sale</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. If the Company
is merged or consolidated with another entity or sells or otherwise disposes of substantially all of its assets to another company while
this Option remain outstanding under this Plan, unless provisions are made in connection with such transaction for the continuance of
this Plan and/or the assumption or substitution of such Option with new options or stock awards covering the stock of the successor company,
or parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices, then this Option, whether
or not vested or then exercisable, shall terminate immediately as of the effective date of any such merger, consolidation or sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">8.&nbsp;<FONT STYLE="background-color: white"><U>Adjustments</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by Section 3.3 of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">9.&nbsp;<FONT STYLE="background-color: white"><U>Tax Liability and Withholding</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related
withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items is and remains the Participant&rsquo;s
responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection
with the grant, vesting, or exercise of the Option or the subsequent sale of any shares acquired on exercise; and (b) does not commit
to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">10.&nbsp;<FONT STYLE="background-color: white"><U>Qualification as an Incentive Stock Option</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
It is understood that this Option is intended to qualify as an incentive stock option as defined in Section 422 of the Code to the extent
permitted under Applicable Law. Accordingly, the Participant understands that in order to obtain the benefits of an incentive stock option,
no sale or other disposition may be made of shares for which incentive stock option treatment is desired within one (1) year following
the date of exercise of the Option or within two (2) years from the Grant Date. The Participant understands and agrees that the Company
shall not be liable or responsible for any additional tax liability the Participant incurs in the event that the Internal Revenue Service
for any reason determines that this Option does not qualify as an incentive stock option within the meaning of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">11.&nbsp;
<FONT STYLE="background-color: white"><U>Disqualifying Disposition</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
If the Participant disposes of the shares of Common Stock prior to the expiration of either two (2) years from the Grant Date or one
(1) year from the date the shares are transferred to the Participant pursuant to the exercise of the Option (a &ldquo;<B>Disqualifying
Disposition</B>&rdquo;), the Participant shall notify the Company in writing within thirty (30) days after such disposition of the date
and <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">terms
of such disposition. The Participant also agrees to provide the Company with any information concerning any such dispositions as the
Company requires for tax purposes.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">12.&nbsp;
<FONT STYLE="background-color: white"><U>Compliance with Law</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The exercise of the Option and the issuance and transfer of shares of Common Stock shall be subject to compliance by the Company and
the Participant with all applicable requirements of federal and state securities laws, regulatory agencies and any stock exchange on
which the Company&rsquo;s shares of Common Stock may be listed. No shares of Common Stock shall be issued pursuant to this Option unless and
until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction
of the Company and its counsel. The Participant understands that the Company is under no obligation to register the shares of Common
Stock with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">13.&nbsp;<FONT STYLE="background-color: white"><U>Notices</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of the Company
at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall be in
writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company. Either party may designate
another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">14.&nbsp;<FONT STYLE="background-color: white"><U>Governing Law</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict of law
principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">15.&nbsp;<FONT STYLE="background-color: white"><U>Interpretation</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Committee for
review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">16.&nbsp;<FONT STYLE="background-color: white"><U>Options Subject to Plan</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and provisions of the Plan as it may be amended
from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein
and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">17.&nbsp;<FONT STYLE="background-color: white"><U>Successors and Assigns</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors
and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Participant
and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this Agreement may be transferred by will or
the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">18.&nbsp;<FONT STYLE="background-color: white"><U>Severability</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of
any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable
to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">19.&nbsp;<FONT STYLE="background-color: white"><U>Discretionary Nature of Plan</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion. The grant of the
Option in this Agreement does not create any contractual right or other right to receive any Options or other Awards in the future. Future
Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not constitute
a change or impairment of the terms and conditions of the Participant&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">20.&nbsp;<FONT STYLE="background-color: white"><U>Amendment</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; <I>provided,
that</I>, no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">21.&nbsp;<FONT STYLE="background-color: white"><U>No Impact on Other Benefits</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation for purposes of calculating any severance,
retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Counterparts</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one
and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable
document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document,
will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">23.&nbsp;<FONT STYLE="background-color: white"><U>Acceptance</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms
and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. The Participant
acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying shares and that
the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signature
page follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-indent: 239.4pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT>INMUNE BIO, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>inmb-20220321.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kk5s7xRiXhun8uNbHcsWa2ByaPtzp95OYlBuGl/fQmabyQqH0LyWyFdO7gmMUYB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:INMB="http://inmunebio.com/20220321" elementFormDefault="qualified" targetNamespace="http://inmunebio.com/20220321">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://inmunebio.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="inmb-20220321_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="inmb-20220321_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>inmb-20220321_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>inmb-20220321_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://inmunebio.com/role/Cover" xlink:href="inmb-20220321.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://inmunebio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140029172461144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 21,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INMUNE BIO INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001711754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5205835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 NE Mizner Blvd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">964 3720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INMB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>ea157245-8k_inmunebio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inmb-20220321.xsd" xlink:type="simple"/>
    <context id="From2022-03-21to2022-03-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-21</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-03-21to2022-03-21">0001711754</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-03-21to2022-03-21">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-03-21to2022-03-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-03-21to2022-03-21">2022-03-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-03-21to2022-03-21">INMUNE BIO INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-03-21to2022-03-21">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-03-21to2022-03-21">001-38793</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-03-21to2022-03-21">47-5205835</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-03-21to2022-03-21">225 NE Mizner Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-03-21to2022-03-21">Suite 640</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-03-21to2022-03-21">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-03-21to2022-03-21">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-03-21to2022-03-21">33432</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-03-21to2022-03-21">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-03-21to2022-03-21">964 3720</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-03-21to2022-03-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-03-21to2022-03-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-03-21to2022-03-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-03-21to2022-03-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-03-21to2022-03-21">Common Stock, par value $0.001 per shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-03-21to2022-03-21">INMB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-03-21to2022-03-21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-03-21to2022-03-21">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-03-21to2022-03-21">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M/UY_ 5!+ 0(4 Q0    (  Z >%0'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ #H!X5/+)L@#M
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ #H!X5)E<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  .@'A4*),S[W@$  ![$0  &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ #H!X5)^@&_"Q @  X@P   T              ( !N@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  .@'A4EXJ[',     3 @  "P
M    @ &6#P  7W)E;',O+G)E;'-02P$"% ,4    "  .@'A4JL0B%C,!   B
M @  #P              @ %_$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ #H!X5"0>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ #H!X5&60>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea157245-8k_inmunebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea157245-8k_inmunebio.htm">ea157245-8k_inmunebio.htm</File>
    <File>ea157245ex10-1_inmunebio.htm</File>
    <File>ea157245ex10-2_inmunebio.htm</File>
    <File>inmb-20220321.xsd</File>
    <File>inmb-20220321_lab.xml</File>
    <File>inmb-20220321_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea157245-8k_inmunebio.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea157245-8k_inmunebio.htm"
     ]
    },
    "labelLink": {
     "local": [
      "inmb-20220321_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inmb-20220321_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "inmb-20220321.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "INMB",
   "nsuri": "http://inmunebio.com/20220321",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea157245-8k_inmunebio.htm",
      "contextRef": "From2022-03-21to2022-03-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://inmunebio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea157245-8k_inmunebio.htm",
      "contextRef": "From2022-03-21to2022-03-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-22-014838-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-014838-xbrl.zip
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M&L?4W2S@ =< T[@H6S:6&P3V+"?2O+H,YFF,@QI!>D),:T#-E]"^+)=YO'&
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ML<;C$G.V$XWAZYS%\(BE)\HM6(.*T,:K,R0@R(;X!%!KA7XHGVE!3,X-*C)
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M,&I$>SQORPZK$Y+X\^L=N2=<SFE8D7W^6>SLL>/,8T"LZ[.ZP<713_)Z X,
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M+ &*0V.$^F0D,(:*4%VT3WS=VC?<TWB+3]PO]\19^\[_4$L! A0#%     @
M#H!X5"*<= %'%    W$  !D              ( !     &5A,34W,C0U+3AK
M7VEN;75N96)I;RYH=&U02P$"% ,4    "  .@'A4#GL)H$4;  #>@   '
M            @ %^%   96$Q-3<R-#5E>#$P+3%?:6YM=6YE8FEO+FAT;5!+
M 0(4 Q0    (  Z >%1ID[U^_!H  !BY   <              "  ?TO  !E
M83$U-S(T-65X,3 M,E]I;FUU;F5B:6\N:'1M4$L! A0#%     @ #H!X5"XE
M6[P\ P  ^ L  !$              ( !,TL  &EN;6(M,C R,C S,C$N>'-D
M4$L! A0#%     @ #H!X5"_BJF#_"@  ;(<  !4              ( !GDX
M &EN;6(M,C R,C S,C%?;&%B+GAM;%!+ 0(4 Q0    (  Z >%0G ?O&4P<
M ,-8   5              "  =!9  !I;FUB+3(P,C(P,S(Q7W!R92YX;6Q0
52P4&      8 !@"@ 0  5F$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
